AU2017423053A1 - Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof - Google Patents

Info

Publication number

AU2017423053A1

AU2017423053A1 AU2017423053A AU2017423053A AU2017423053A1 AU 2017423053 A1 AU2017423053 A1 AU 2017423053A1 AU 2017423053 A AU2017423053 A AU 2017423053A AU 2017423053 A AU2017423053 A AU 2017423053A AU 2017423053 A1 AU2017423053 A1 AU 2017423053A1

Authority

AU

Australia

Prior art keywords

lipid

peptide

pharmaceutical composition

antigen

peptide antigens

Prior art date

2017-07-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 150000002632 lipids Chemical class 0.000 title claims abstract description 460
• 239000002245 particle Substances 0.000 title claims abstract description 312
• 238000000034 method Methods 0.000 title claims abstract description 285
• 238000002360 preparation method Methods 0.000 title claims abstract description 131
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 117
• 239000003814 drug Substances 0.000 claims abstract description 293
• 229940124597 therapeutic agent Drugs 0.000 claims abstract description 275
• 239000012051 hydrophobic carrier Substances 0.000 claims abstract description 98
• 230000028993 immune response Effects 0.000 claims abstract description 64
• 239000002356 single layer Substances 0.000 claims abstract description 32
• 230000001939 inductive effect Effects 0.000 claims abstract description 22
• 238000011282 treatment Methods 0.000 claims abstract description 21
• 239000000427 antigen Substances 0.000 claims description 451
• 108091007433 antigens Proteins 0.000 claims description 447
• 102000036639 antigens Human genes 0.000 claims description 447
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 422
• 239000000203 mixture Substances 0.000 claims description 285
• 206010028980 Neoplasm Diseases 0.000 claims description 73
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 69
• 150000001413 amino acids Chemical class 0.000 claims description 54
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 52
• 201000011510 cancer Diseases 0.000 claims description 50
• 238000001035 drying Methods 0.000 claims description 48
• 239000002671 adjuvant Substances 0.000 claims description 46
• 238000004108 freeze drying Methods 0.000 claims description 45
• 238000002156 mixing Methods 0.000 claims description 45
• 108010002687 Survivin Proteins 0.000 claims description 43
• 230000002209 hydrophobic effect Effects 0.000 claims description 37
• 229920001184 polypeptide Polymers 0.000 claims description 35
• 241000725643 Respiratory syncytial virus Species 0.000 claims description 31
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 31
• 239000001632 sodium acetate Substances 0.000 claims description 31
• 235000017281 sodium acetate Nutrition 0.000 claims description 31
• 239000012634 fragment Substances 0.000 claims description 30
• 230000005847 immunogenicity Effects 0.000 claims description 29
• 239000001488 sodium phosphate Substances 0.000 claims description 28
• 229910000162 sodium phosphate Inorganic materials 0.000 claims description 28
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 28
• SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 26
• 235000012000 cholesterol Nutrition 0.000 claims description 26
• 108020004414 DNA Proteins 0.000 claims description 25
• 239000002480 mineral oil Substances 0.000 claims description 25
• 102000004127 Cytokines Human genes 0.000 claims description 24
• 108090000695 Cytokines Proteins 0.000 claims description 24
• 108091027757 Deoxyribozyme Proteins 0.000 claims description 23
• 239000002502 liposome Substances 0.000 claims description 23
• 235000010446 mineral oil Nutrition 0.000 claims description 23
• 239000013566 allergen Substances 0.000 claims description 21
• 241000701806 Human papillomavirus Species 0.000 claims description 20
• 238000011146 sterile filtration Methods 0.000 claims description 19
• 238000004128 high performance liquid chromatography Methods 0.000 claims description 18
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 17
• 208000015181 infectious disease Diseases 0.000 claims description 17
• 229940126586 small molecule drug Drugs 0.000 claims description 17
• 108090000994 Catalytic RNA Proteins 0.000 claims description 16
• 102000053642 Catalytic RNA Human genes 0.000 claims description 16
• 108091092562 ribozyme Proteins 0.000 claims description 16
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
• 230000003381 solubilizing effect Effects 0.000 claims description 15
• 239000000693 micelle Substances 0.000 claims description 14
• 239000002773 nucleotide Substances 0.000 claims description 14
• 125000003729 nucleotide group Chemical group 0.000 claims description 14
• 238000004513 sizing Methods 0.000 claims description 14
• 241000193738 Bacillus anthracis Species 0.000 claims description 13
• 230000000717 retained effect Effects 0.000 claims description 13
• 230000002452 interceptive effect Effects 0.000 claims description 12
• 108020005544 Antisense RNA Proteins 0.000 claims description 11
• 239000003184 complementary RNA Substances 0.000 claims description 11
• 229940088597 hormone Drugs 0.000 claims description 11
• 239000005556 hormone Substances 0.000 claims description 11
• 239000002244 precipitate Substances 0.000 claims description 11
• 208000035473 Communicable disease Diseases 0.000 claims description 10
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
• 230000002441 reversible effect Effects 0.000 claims description 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
• 229940125385 biologic drug Drugs 0.000 claims description 8
• 229940049964 oleate Drugs 0.000 claims description 8
• 229940065181 bacillus anthracis Drugs 0.000 claims description 7
• 241000224016 Plasmodium Species 0.000 claims description 6
• 230000015556 catabolic process Effects 0.000 claims description 5
• 238000006731 degradation reaction Methods 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 230000004931 aggregating effect Effects 0.000 claims description 4
• 239000002243 precursor Substances 0.000 claims description 4
• 238000011068 loading method Methods 0.000 claims description 3
• 238000007789 sealing Methods 0.000 claims description 3
• 239000007921 spray Substances 0.000 claims description 2
• 238000001694 spray drying Methods 0.000 claims description 2
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 3
• 102000000763 Survivin Human genes 0.000 claims 2
• 210000004027 cell Anatomy 0.000 description 68
• 239000000243 solution Substances 0.000 description 58
• 239000002904 solvent Substances 0.000 description 58
• 108090000623 proteins and genes Proteins 0.000 description 57
• 235000001014 amino acid Nutrition 0.000 description 56
• 102000040430 polynucleotide Human genes 0.000 description 50
• 108091033319 polynucleotide Proteins 0.000 description 50
• 239000002157 polynucleotide Substances 0.000 description 50
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 48
• 102000004169 proteins and genes Human genes 0.000 description 48
• 239000012528 membrane Substances 0.000 description 44
• 235000018102 proteins Nutrition 0.000 description 44
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
• 239000000126 substance Substances 0.000 description 38
• 229920002477 rna polymer Polymers 0.000 description 35
• 239000000306 component Substances 0.000 description 34
• 210000003719 b-lymphocyte Anatomy 0.000 description 29
• 201000010099 disease Diseases 0.000 description 25
• 238000005063 solubilization Methods 0.000 description 25
• 230000007928 solubilization Effects 0.000 description 25
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
• 238000009472 formulation Methods 0.000 description 23
• 239000003921 oil Substances 0.000 description 21
• 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 20
• 241000282414 Homo sapiens Species 0.000 description 20
• 230000014509 gene expression Effects 0.000 description 20
• 238000004519 manufacturing process Methods 0.000 description 20
• 235000019198 oils Nutrition 0.000 description 18
• 241000700605 Viruses Species 0.000 description 17
• 210000002443 helper t lymphocyte Anatomy 0.000 description 17
• 229960005486 vaccine Drugs 0.000 description 17
• 239000013598 vector Substances 0.000 description 17
• 230000035772 mutation Effects 0.000 description 16
• 244000052769 pathogen Species 0.000 description 16
• 239000004055 small Interfering RNA Substances 0.000 description 15
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 210000000612 antigen-presenting cell Anatomy 0.000 description 14
• 229940022399 cancer vaccine Drugs 0.000 description 14
• 238000009566 cancer vaccine Methods 0.000 description 14
• 238000001125 extrusion Methods 0.000 description 14
• 230000021633 leukocyte mediated immunity Effects 0.000 description 14
• 108020004999 messenger RNA Proteins 0.000 description 14
• 108020004459 Small interfering RNA Proteins 0.000 description 13
• 208000035475 disorder Diseases 0.000 description 13
• 239000000463 material Substances 0.000 description 13
• 239000002679 microRNA Substances 0.000 description 13
• 150000003904 phospholipids Chemical class 0.000 description 13
• 239000000843 powder Substances 0.000 description 13
• 108700011259 MicroRNAs Proteins 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 230000008569 process Effects 0.000 description 12
• 230000001105 regulatory effect Effects 0.000 description 12
• 238000002255 vaccination Methods 0.000 description 12
• 229960004784 allergens Drugs 0.000 description 11
• 238000003556 assay Methods 0.000 description 11
• 230000028996 humoral immune response Effects 0.000 description 11
• 239000004417 polycarbonate Substances 0.000 description 11
• 229920000515 polycarbonate Polymers 0.000 description 11
• 230000002265 prevention Effects 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 230000004044 response Effects 0.000 description 11
• 230000001580 bacterial effect Effects 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 239000010410 layer Substances 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 9
• 101150004362 A15L gene Proteins 0.000 description 9
• 101150064127 A16L gene Proteins 0.000 description 9
• 101100377698 Vaccinia virus (strain Western Reserve) VACWR136 gene Proteins 0.000 description 9
• 230000008901 benefit Effects 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 230000002163 immunogen Effects 0.000 description 9
• 239000000787 lecithin Substances 0.000 description 9
• 229940067606 lecithin Drugs 0.000 description 9
• 235000010445 lecithin Nutrition 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 238000012545 processing Methods 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• -1 without limitation Chemical class 0.000 description 9
• 108091054437 MHC class I family Proteins 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 230000001717 pathogenic effect Effects 0.000 description 8
• 230000001954 sterilising effect Effects 0.000 description 8
• 230000014616 translation Effects 0.000 description 8
• 241000711920 Human orthopneumovirus Species 0.000 description 7
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 102000043129 MHC class I family Human genes 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
• 108091008874 T cell receptors Proteins 0.000 description 7
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
• 230000003213 activating effect Effects 0.000 description 7
• 239000000470 constituent Substances 0.000 description 7
• IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 239000000539 dimer Substances 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 7
• 230000003053 immunization Effects 0.000 description 7
• 238000002649 immunization Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 150000003384 small molecules Chemical class 0.000 description 7
• 238000004659 sterilization and disinfection Methods 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical group [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 6
• 230000004543 DNA replication Effects 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
• 102100037850 Interferon gamma Human genes 0.000 description 6
• 108010050904 Interferons Proteins 0.000 description 6
• 102000014150 Interferons Human genes 0.000 description 6
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
• 108091027967 Small hairpin RNA Proteins 0.000 description 6
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 210000000987 immune system Anatomy 0.000 description 6
• 238000009169 immunotherapy Methods 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 201000004792 malaria Diseases 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 239000002105 nanoparticle Substances 0.000 description 6
• 238000000235 small-angle X-ray scattering Methods 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
• 229940045513 CTLA4 antagonist Drugs 0.000 description 5
• 101710117490 Circumsporozoite protein Proteins 0.000 description 5
• 241000701022 Cytomegalovirus Species 0.000 description 5
• 101710154606 Hemagglutinin Proteins 0.000 description 5
• GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 5
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 5
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
• 101710176177 Protein A56 Proteins 0.000 description 5
• 230000033289 adaptive immune response Effects 0.000 description 5
• 238000013459 approach Methods 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 150000004665 fatty acids Chemical group 0.000 description 5
• 230000002349 favourable effect Effects 0.000 description 5
• 239000000185 hemagglutinin Substances 0.000 description 5
• 230000003308 immunostimulating effect Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 5
• 229940023041 peptide vaccine Drugs 0.000 description 5
• 239000004033 plastic Substances 0.000 description 5
• 229920003023 plastic Polymers 0.000 description 5
• 230000008707 rearrangement Effects 0.000 description 5
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 108010074708 B7-H1 Antigen Proteins 0.000 description 4
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
• 241000709661 Enterovirus Species 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108091054438 MHC class II family Proteins 0.000 description 4
• 102000043131 MHC class II family Human genes 0.000 description 4
• 239000002033 PVDF binder Substances 0.000 description 4
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
• 230000024932 T cell mediated immunity Effects 0.000 description 4
• 241000700618 Vaccinia virus Species 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 230000005875 antibody response Effects 0.000 description 4
• 230000007969 cellular immunity Effects 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 238000012790 confirmation Methods 0.000 description 4
• 229960004397 cyclophosphamide Drugs 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 229940023064 escherichia coli Drugs 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 238000007710 freezing Methods 0.000 description 4
• 230000008014 freezing Effects 0.000 description 4
• 150000004676 glycans Chemical class 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• 229940079322 interferon Drugs 0.000 description 4
• 239000000178 monomer Substances 0.000 description 4
• 238000006386 neutralization reaction Methods 0.000 description 4
• 239000010466 nut oil Substances 0.000 description 4
• 235000019488 nut oil Nutrition 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 229920001282 polysaccharide Polymers 0.000 description 4
• 239000005017 polysaccharide Substances 0.000 description 4
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
• 230000009467 reduction Effects 0.000 description 4
• 102220085507 rs776346547 Human genes 0.000 description 4
• 238000001464 small-angle X-ray scattering data Methods 0.000 description 4
• 238000000527 sonication Methods 0.000 description 4
• 230000004936 stimulating effect Effects 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• 241000712461 unidentified influenza virus Species 0.000 description 4
• 235000015112 vegetable and seed oil Nutrition 0.000 description 4
• 239000008158 vegetable oil Substances 0.000 description 4
• 230000009385 viral infection Effects 0.000 description 4
• WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 3
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 3
• 241001115402 Ebolavirus Species 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 108010035452 HLA-A1 Antigen Proteins 0.000 description 3
• 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
• 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
• 108010086377 HLA-A3 Antigen Proteins 0.000 description 3
• 241000711549 Hepacivirus C Species 0.000 description 3
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 3
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 102000009151 Luteinizing Hormone Human genes 0.000 description 3
• 108010073521 Luteinizing Hormone Proteins 0.000 description 3
• 241000712079 Measles morbillivirus Species 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 108010006232 Neuraminidase Proteins 0.000 description 3
• 102000005348 Neuraminidase Human genes 0.000 description 3
• 241000223960 Plasmodium falciparum Species 0.000 description 3
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
• 101710194807 Protective antigen Proteins 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
• 241000607142 Salmonella Species 0.000 description 3
• 241000607768 Shigella Species 0.000 description 3
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
• 108010055044 Tetanus Toxin Proteins 0.000 description 3
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 3
• 235000018936 Vitellaria paradoxa Nutrition 0.000 description 3
• 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 238000004630 atomic force microscopy Methods 0.000 description 3
• 230000031018 biological processes and functions Effects 0.000 description 3
• 229940028617 conventional vaccine Drugs 0.000 description 3
• 101150028842 ctxA gene Proteins 0.000 description 3
• 229940104302 cytosine Drugs 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 206010013023 diphtheria Diseases 0.000 description 3
• 239000003925 fat Substances 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 230000009368 gene silencing by RNA Effects 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• 230000001965 increasing effect Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 229940040129 luteinizing hormone Drugs 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 3
• 244000045947 parasite Species 0.000 description 3
• 229960002621 pembrolizumab Drugs 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 239000011148 porous material Substances 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 238000012163 sequencing technique Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000012064 sodium phosphate buffer Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 3
• 230000000087 stabilizing effect Effects 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 229940118376 tetanus toxin Drugs 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
• 206010069754 Acquired gene mutation Diseases 0.000 description 2
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
• 241000713826 Avian leukosis virus Species 0.000 description 2
• 241000588832 Bordetella pertussis Species 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 241000589562 Brucella Species 0.000 description 2
• 102100038078 CD276 antigen Human genes 0.000 description 2
• 101150013553 CD40 gene Proteins 0.000 description 2
• 241001493160 California encephalitis virus Species 0.000 description 2
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
• 241001647372 Chlamydia pneumoniae Species 0.000 description 2
• 241001647378 Chlamydia psittaci Species 0.000 description 2
• 206010008631 Cholera Diseases 0.000 description 2
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
• 241000193155 Clostridium botulinum Species 0.000 description 2
• 241000223205 Coccidioides immitis Species 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 241000711573 Coronaviridae Species 0.000 description 2
• 241000700626 Cowpox virus Species 0.000 description 2
• 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• 241000725619 Dengue virus Species 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 241000991587 Enterovirus C Species 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• 241001646719 Escherichia coli O157:H7 Species 0.000 description 2
• 201000001342 Fallopian tube cancer Diseases 0.000 description 2
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
• 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 102220516182 Glutamate receptor ionotropic, NMDA 2B_C51S_mutation Human genes 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
• 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
• 108010013476 HLA-A24 Antigen Proteins 0.000 description 2
• 108010091938 HLA-B7 Antigen Proteins 0.000 description 2
• 241000606768 Haemophilus influenzae Species 0.000 description 2
• 241000150562 Hantaan orthohantavirus Species 0.000 description 2
• 241000590002 Helicobacter pylori Species 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 241000709721 Hepatovirus A Species 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 2
• 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
• 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
• 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
• 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 2
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
• 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 2
• 241000598171 Human adenovirus sp. Species 0.000 description 2
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 241000712431 Influenza A virus Species 0.000 description 2
• 241000713196 Influenza B virus Species 0.000 description 2
• 241000713297 Influenza C virus Species 0.000 description 2
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 241000710842 Japanese encephalitis virus Species 0.000 description 2
• 241000589248 Legionella Species 0.000 description 2
• 208000007764 Legionnaires' Disease Diseases 0.000 description 2
• 241000589902 Leptospira Species 0.000 description 2
• 241000186781 Listeria Species 0.000 description 2
• 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
• 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
• 241000579048 Merkel cell polyomavirus Species 0.000 description 2
• 241000711386 Mumps virus Species 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 241000186359 Mycobacterium Species 0.000 description 2
• 241000202934 Mycoplasma pneumoniae Species 0.000 description 2
• 241001263478 Norovirus Species 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 241000702244 Orthoreovirus Species 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 description 2
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
• 102000003982 Parathyroid hormone Human genes 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 201000005702 Pertussis Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 241000223801 Plasmodium knowlesi Species 0.000 description 2
• 241000223821 Plasmodium malariae Species 0.000 description 2
• 241001505293 Plasmodium ovale Species 0.000 description 2
• 241000223810 Plasmodium vivax Species 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 241000711902 Pneumovirus Species 0.000 description 2
• 241001505332 Polyomavirus sp. Species 0.000 description 2
• WHNJMTHJGCEKGA-ULQDDVLXSA-N Pro-Phe-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WHNJMTHJGCEKGA-ULQDDVLXSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 241000125945 Protoparvovirus Species 0.000 description 2
• 241000621172 Pseudocowpox virus Species 0.000 description 2
• 241000711798 Rabies lyssavirus Species 0.000 description 2
• 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 2
• 241000702670 Rotavirus Species 0.000 description 2
• 241000710799 Rubella virus Species 0.000 description 2
• 241000837158 Senecavirus A Species 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 102100022831 Somatoliberin Human genes 0.000 description 2
• 101710142969 Somatoliberin Proteins 0.000 description 2
• 102100038803 Somatotropin Human genes 0.000 description 2
• NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
• 241000191940 Staphylococcus Species 0.000 description 2
• 229930182558 Sterol Natural products 0.000 description 2
• 241000193998 Streptococcus pneumoniae Species 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 210000004241 Th2 cell Anatomy 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
• 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
• 241000607626 Vibrio cholerae Species 0.000 description 2
• 241000710886 West Nile virus Species 0.000 description 2
• 238000002441 X-ray diffraction Methods 0.000 description 2
• 241000710772 Yellow fever virus Species 0.000 description 2
• 241000607447 Yersinia enterocolitica Species 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 229960000583 acetic acid Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 230000030741 antigen processing and presentation Effects 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 238000005315 distribution function Methods 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000000688 enterotoxigenic effect Effects 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 229940028334 follicle stimulating hormone Drugs 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 229940047650 haemophilus influenzae Drugs 0.000 description 2
• 229940037467 helicobacter pylori Drugs 0.000 description 2
• 238000000265 homogenisation Methods 0.000 description 2
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 239000012678 infectious agent Substances 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000015788 innate immune response Effects 0.000 description 2
• 229940028843 inosinic acid Drugs 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 210000000265 leukocyte Anatomy 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 108091070501 miRNA Proteins 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
• 229960003301 nivolumab Drugs 0.000 description 2
• 239000000199 parathyroid hormone Substances 0.000 description 2
• 229960001319 parathyroid hormone Drugs 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 201000002628 peritoneum cancer Diseases 0.000 description 2
• 229940038309 personalized vaccine Drugs 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
• YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• 229940118768 plasmodium malariae Drugs 0.000 description 2
• 239000013573 pollen allergen Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• 235000011121 sodium hydroxide Nutrition 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 230000037439 somatic mutation Effects 0.000 description 2
• 235000012424 soybean oil Nutrition 0.000 description 2
• 239000003549 soybean oil Substances 0.000 description 2
• 150000003432 sterols Chemical class 0.000 description 2
• 235000003702 sterols Nutrition 0.000 description 2
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
• 238000010254 subcutaneous injection Methods 0.000 description 2
• 239000007929 subcutaneous injection Substances 0.000 description 2
• 238000000859 sublimation Methods 0.000 description 2
• 230000008022 sublimation Effects 0.000 description 2
• 238000011191 terminal modification Methods 0.000 description 2
• 229960000814 tetanus toxoid Drugs 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 230000037455 tumor specific immune response Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229940118696 vibrio cholerae Drugs 0.000 description 2
• 238000003260 vortexing Methods 0.000 description 2
• 238000010792 warming Methods 0.000 description 2
• 229940051021 yellow-fever virus Drugs 0.000 description 2
• 229940098232 yersinia enterocolitica Drugs 0.000 description 2
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 1
• SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
• 241000238876 Acari Species 0.000 description 1
• 241000251468 Actinopterygii Species 0.000 description 1
• 101150051188 Adora2a gene Proteins 0.000 description 1
• ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
• VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 241000208841 Ambrosia trifida Species 0.000 description 1
• 241000256844 Apis mellifera Species 0.000 description 1
• 241000239223 Arachnida Species 0.000 description 1
• JOADBFCFJGNIKF-GUBZILKMSA-N Arg-Met-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O JOADBFCFJGNIKF-GUBZILKMSA-N 0.000 description 1
• 241000244186 Ascaris Species 0.000 description 1
• HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
• VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 1
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 108091007065 BIRCs Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 241000537222 Betabaculovirus Species 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• 241000711895 Bovine orthopneumovirus Species 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
• 102100024263 CD160 antigen Human genes 0.000 description 1
• 102100038077 CD226 antigen Human genes 0.000 description 1
• 102100027207 CD27 antigen Human genes 0.000 description 1
• 102100025221 CD70 antigen Human genes 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 241000178270 Canarypox virus Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000238424 Crustacea Species 0.000 description 1
• 240000005109 Cryptomeria japonica Species 0.000 description 1
• HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 1
• 229930183912 Cytidylic acid Natural products 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 230000000970 DNA cross-linking effect Effects 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000007018 DNA scission Effects 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 108010044052 Desmin Proteins 0.000 description 1
• 102100036912 Desmin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 101100425960 Escherichia coli traT gene Proteins 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 102100031351 Galectin-9 Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 101100229077 Gallus gallus GAL9 gene Proteins 0.000 description 1
• 241000699694 Gerbillinae Species 0.000 description 1
• UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
• AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
• TUTIHHSZKFBMHM-WHFBIAKZSA-N Glu-Asn Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O TUTIHHSZKFBMHM-WHFBIAKZSA-N 0.000 description 1
• APHGWLWMOXGZRL-DCAQKATOSA-N Glu-Glu-His Chemical compound N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O APHGWLWMOXGZRL-DCAQKATOSA-N 0.000 description 1
• CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
• JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 1
• QNJNPKSWAHPYGI-JYJNAYRXSA-N Glu-Phe-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 QNJNPKSWAHPYGI-JYJNAYRXSA-N 0.000 description 1
• UDEPRBFQTWGLCW-CIUDSAMLSA-N Glu-Pro-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O UDEPRBFQTWGLCW-CIUDSAMLSA-N 0.000 description 1
• HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
• JVYNYWXHZWVJEF-NUMRIWBASA-N Glu-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O JVYNYWXHZWVJEF-NUMRIWBASA-N 0.000 description 1
• 102000051325 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 108060003393 Granulin Proteins 0.000 description 1
• 102100021186 Granulysin Human genes 0.000 description 1
• 101710168479 Granulysin Proteins 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 241000696272 Gull adenovirus Species 0.000 description 1
• JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 1
• NIKBMHGRNAPJFW-IUCAKERBSA-N His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 NIKBMHGRNAPJFW-IUCAKERBSA-N 0.000 description 1
• RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
• WYWBYSPRCFADBM-GARJFASQSA-N His-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O WYWBYSPRCFADBM-GARJFASQSA-N 0.000 description 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
• 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 1
• 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
• 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 1
• 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
• 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
• 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
• 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 1
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 1
• 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 238000004566 IR spectroscopy Methods 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 1
• 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 1
• 102100021317 Inducible T-cell costimulator Human genes 0.000 description 1
• 101710205775 Inducible T-cell costimulator Proteins 0.000 description 1
• 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 102000014429 Insulin-like growth factor Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• 241000186660 Lactobacillus Species 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 description 1
• NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
• URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
• 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 108010028921 Lipopeptides Proteins 0.000 description 1
• 241000209082 Lolium Species 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
• ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
• JQSIGLHQNSZZRL-KKUMJFAQSA-N Lys-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N JQSIGLHQNSZZRL-KKUMJFAQSA-N 0.000 description 1
• 239000007993 MOPS buffer Substances 0.000 description 1
• 101710164702 Major outer membrane protein Proteins 0.000 description 1
• 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
• WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
• YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
• CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
• AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
• 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
• 108020001621 Natriuretic Peptide Proteins 0.000 description 1
• 102000004571 Natriuretic peptide Human genes 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
• SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 241000712464 Orthomyxoviridae Species 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• 101800000989 Oxytocin Proteins 0.000 description 1
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
• 108010036616 P18-I10 peptide Proteins 0.000 description 1
• 241000392928 Parachromis friedrichsthalii Species 0.000 description 1
• 241000711504 Paramyxoviridae Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 description 1
• WLYPRKLMRIYGPP-JYJNAYRXSA-N Phe-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 WLYPRKLMRIYGPP-JYJNAYRXSA-N 0.000 description 1
• PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
• GKZIWHRNKRBEOH-HOTGVXAUSA-N Phe-Phe Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)C1=CC=CC=C1 GKZIWHRNKRBEOH-HOTGVXAUSA-N 0.000 description 1
• 241001442539 Plasmodium sp. Species 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
• FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108091093078 Pyrimidine dimer Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 102000003743 Relaxin Human genes 0.000 description 1
• 108090000103 Relaxin Proteins 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108010057163 Ribonuclease III Proteins 0.000 description 1
• 102000003661 Ribonuclease III Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 101000801721 Schistosoma mansoni Triosephosphate isomerase Proteins 0.000 description 1
• SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
• 108010022999 Serine Proteases Proteins 0.000 description 1
• 102000012479 Serine Proteases Human genes 0.000 description 1
• 241000287219 Serinus canaria Species 0.000 description 1
• 241000607762 Shigella flexneri Species 0.000 description 1
• 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
• 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 101710200413 Small hydrophobic protein Proteins 0.000 description 1
• 241000517830 Solenopsis geminata Species 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 102000005157 Somatostatin Human genes 0.000 description 1
• 108010056088 Somatostatin Proteins 0.000 description 1
• 240000002439 Sorghum halepense Species 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• 241000194026 Streptococcus gordonii Species 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• RFKVQLIXNVEOMB-WEDXCCLWSA-N Thr-Leu-Gly Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N)O RFKVQLIXNVEOMB-WEDXCCLWSA-N 0.000 description 1
• VGYVVSQFSSKZRJ-OEAJRASXSA-N Thr-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@H](O)C)CC1=CC=CC=C1 VGYVVSQFSSKZRJ-OEAJRASXSA-N 0.000 description 1
• XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
• GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• 102000002689 Toll-like receptor Human genes 0.000 description 1
• 108020000411 Toll-like receptor Proteins 0.000 description 1
• 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• KDWZQYUTMJSYRJ-BHYGNILZSA-N Trp-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O KDWZQYUTMJSYRJ-BHYGNILZSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
• 206010046865 Vaccinia virus infection Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000256856 Vespidae Species 0.000 description 1
• 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical compound N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 150000008065 acid anhydrides Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 238000007792 addition Methods 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000006154 adenylylation Effects 0.000 description 1
• 239000013567 aeroallergen Substances 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
• 108010005233 alanylglutamic acid Proteins 0.000 description 1
• 108010087924 alanylproline Proteins 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 150000001414 amino alcohols Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 230000001754 anti-pyretic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000006023 anti-tumor response Effects 0.000 description 1
• 229940127090 anticoagulant agent Drugs 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940124538 antidiuretic agent Drugs 0.000 description 1
• 239000003160 antidiuretic agent Substances 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 239000002282 antimigraine agent Substances 0.000 description 1
• 229940125684 antimigraine agent Drugs 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 229940125716 antipyretic agent Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000013011 aqueous formulation Substances 0.000 description 1
• 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 108010001271 arginyl-glutamyl-arginine Proteins 0.000 description 1
• 108010062796 arginyllysine Proteins 0.000 description 1
• 108010093581 aspartyl-proline Proteins 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 206010064097 avian influenza Diseases 0.000 description 1
• 239000013570 bacterial allergen Substances 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 239000003012 bilayer membrane Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 239000012503 blood component Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 125000002091 cationic group Chemical class 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 230000005889 cellular cytotoxicity Effects 0.000 description 1
• 230000004640 cellular pathway Effects 0.000 description 1
• 229940125693 central nervous system agent Drugs 0.000 description 1
• 239000003576 central nervous system agent Substances 0.000 description 1
• 229940106189 ceramide Drugs 0.000 description 1
• ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 235000020971 citrus fruits Nutrition 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
• 238000011266 cytolytic assay Methods 0.000 description 1
• 238000007822 cytometric assay Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000022811 deglycosylation Effects 0.000 description 1
• 239000008380 degradant Substances 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 210000005045 desmin Anatomy 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 229950006137 dexfosfoserine Drugs 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229910003460 diamond Inorganic materials 0.000 description 1
• 239000010432 diamond Substances 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical class [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 229950009791 durvalumab Drugs 0.000 description 1
• 238000002296 dynamic light scattering Methods 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229950006370 epacadostat Drugs 0.000 description 1
• 125000001901 erucoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 125000001924 fatty-acyl group Chemical group 0.000 description 1
• 239000012847 fine chemical Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000013568 food allergen Substances 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 102000054766 genetic haplotypes Human genes 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 150000002327 glycerophospholipids Chemical class 0.000 description 1
• 108010084389 glycyltryptophan Proteins 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000013574 grass pollen allergen Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000035931 haemagglutination Effects 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 229920000140 heteropolymer Polymers 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 230000036571 hydration Effects 0.000 description 1
• 238000006703 hydration reaction Methods 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 229940126546 immune checkpoint molecule Drugs 0.000 description 1
• 239000012642 immune effector Substances 0.000 description 1
• 230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 235000013902 inosinic acid Nutrition 0.000 description 1
• 239000004245 inosinic acid Substances 0.000 description 1
• 229950000038 interferon alfa Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 101150027374 irgA gene Proteins 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940039696 lactobacillus Drugs 0.000 description 1
• 239000005001 laminate film Substances 0.000 description 1
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 108010034529 leucyl-lysine Proteins 0.000 description 1
• 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
• 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 108091005446 macrophage receptors Proteins 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 238000006263 metalation reaction Methods 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 239000002086 nanomaterial Substances 0.000 description 1
• 230000003533 narcotic effect Effects 0.000 description 1
• 239000000692 natriuretic peptide Substances 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 239000012454 non-polar solvent Substances 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
• 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
• 229960001723 oxytocin Drugs 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 229930192851 perforin Natural products 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000000634 powder X-ray diffraction Methods 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000020978 protein processing Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 244000079416 protozoan pathogen Species 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 150000003338 secosteroids Chemical class 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 210000004215 spore Anatomy 0.000 description 1
• 210000003046 sporozoite Anatomy 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 230000002311 subsequent effect Effects 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 108010044292 tryptophyltyrosine Proteins 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 239000002691 unilamellar liposome Substances 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 208000007089 vaccinia Diseases 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 239000013571 viral allergen Substances 0.000 description 1
• 244000052613 viral pathogen Species 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000007482 whole exome sequencing Methods 0.000 description 1
• 238000012070 whole genome sequencing analysis Methods 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1